论文部分内容阅读
The Cre-loxP system was introduced in theproduction of recombinant AAV (rAAV). Defective adenovi-rus AdLC was used as the helper virus. While doing themass production of recombinant AAV carrying EGFP orhuman clotting factor Ⅸ (hFⅨ) gene, the generation ofhelper virus was significantly limited, it increased the sim-plicity of rAAV purification. The results from in vivo study demonstrated the superiority of this method. This systemprovides a novel approach for the application of rAAV sys-tem in gene therapy.
The Cre-loxP system was introduced in the production of recombinant AAV (rAAV). Defective adenovi-rus AdLC was used as the helper virus. While doing the mass production of recombinant AAV carrying EGFP orhuman clotting factor IX (hFIX) gene, the generation of helper virus was significantly limited, it increased the sim-plicity of rAAV purification. The results from in vivo study demonstrated superiority of this method. This systemprovides a novel approach for the application of rAAV sys-tem in gene therapy.